



Effective Date..... 4/1/2023  
Next Review Date..... 4/1/2024  
Coverage Policy Number ..... IP0334

# Hereditary Angioedema – Lanadelumab-flyo

## Table of Contents

Overview ..... 1  
Initial Approval Criteria..... 1  
Continuation of Therapy ..... 2  
Authorization Duration ..... 2  
Conditions Not Covered..... 2  
Coding Information ..... 3  
Background..... 3  
References ..... 3

## Related Coverage Resources

### INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

## Overview

This policy supports medical necessity review for lanadelumab-flyo (Takhzyro®).

Receipt of sample product does not satisfy any criteria requirements for coverage.

## Initial Approval Criteria

**Lanadelumab-flyo (Takhzyro) is considered medically necessary for Hereditary Angioedema (HAE), Prophylaxis when the individual meets ALL of the following criteria:**

1. Documentation of HAE by **ONE** of the following:
  - a. Confirmed pathogenic variant in the *SERPING1*, *F12*, *ANGPT1*, *PLG* or *KNG1* gene
  - b. One C4 level below the lower limit of normal as defined by the laboratory performing the test and **ONE** of the following:

- i. Has low levels of functional C1-INH protein (less than 50% of normal) at baseline, as documented by laboratory reference values
  - ii. Has low C1-INH antigenic levels (less than 50% of normal) at baseline, as documented by laboratory reference values
2. History of recurrent angioedema in the absence of concomitant urticaria and no concomitant use of medication known to cause angioedema
3. Takhzyro will not be concomitantly administered with other FDA-approved prophylactic treatments for HAE (for example, Cinryze®, Haegarda®, or Orladeyo®)
4. Medication is prescribed by, or in consultation with, an allergist/immunologist or a prescriber who specializes in the treatment of HAE or related disorders

**Dosing.** ONE of the following dosing regimens:

1. 12 years of age and older: The dose is up to 300 mg per injection, administered subcutaneously no more frequently than once every 2 weeks
2. 6 years of age to less than 12 years of age: The dose is up to 150 mg per injection, administered subcutaneously no more frequently than once every 2 weeks
3. Less than 6 years of age: The dose is up to 150 mg per injection, administered subcutaneously no more frequently than once every 4 week

When coverage is available and medically necessary, the dosage, frequency, duration of therapy, and site of care should be reasonable, clinically appropriate, and supported by evidence-based literature and adjusted based upon severity, alternative available treatments, and previous response to therapy.

## Continuation of Therapy

Continuation of lanadelumab-flyo (Takhzyro) is considered medically necessary for HAE prophylaxis when initial criteria are met **AND**:

1. Beneficial response is demonstrated by a decrease in **ANY** of the following:
  - a. HAE acute attack frequency
  - b. HAE attack severity
  - c. Duration of HAE attacks
2. Takhzyro will not be concomitantly administered with other FDA-approved prophylactic treatments for HAE (for example, Cinryze, Haegarda, or Orladeyo)

## Authorization Duration

Initial and reauthorization approval duration: up to 12 months

## Conditions Not Covered

Any other use is considered experimental, investigational or unproven, including the following (this list may not be all inclusive):

**Concomitant Use with Other Hereditary Angioedema (HAE) Prophylactic Therapies.**

Takhzyro has not been studied in combination with other prophylactic therapies for HAE, and combination therapy for long-term prophylactic use is not recommended. Patients may use other medications, including Cinryze (C1 esterase inhibitor [human] intravenous infusion), for on-demand treatment of acute HAE attacks, and for short-term (procedural) prophylaxis. Examples of other HAE prophylactic therapies include Cinryze (C1 esterase inhibitor [human] intravenous infusion), Haegarda (C1 esterase inhibitor [human] subcutaneous injection), and Orladeyo (berotralstat capsules).

**C1-Inhibitor normal (levels and function) episodes of angioedema not related to a documented pathogenic variant in the *F12*, *ANGPT1*, *PLG*, or *KNG1* gene.**

## Coding Information

- 1) This list of codes may not be all-inclusive.
- 2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

HCPCS Codes	Description
J0593	Injection, lanadelumab-flyo, 1 mg (Code may be used for Medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)

## Background

### OVERVIEW

Takhzyro, a human monoclonal antibody inhibitor of plasma kallikrein, is indicated for **prophylaxis to prevent attacks of hereditary angioedema (HAE)** in patients  $\geq 2$  years of age.<sup>1</sup>

### Guidelines

According to US HAE Association Medical Advisory Board Guidelines (2020), when HAE is suspected based on clinical presentation, appropriate testing includes measurement of the serum C4 level, C1 esterase inhibitor (C1-INH) antigenic level, and C1-INH functional level.<sup>2</sup> Low C4 plus low C1-INH antigenic or functional level is consistent with a diagnosis of HAE types I/II. The decision on when to use long-term prophylaxis cannot be made on rigid criteria but should reflect the needs of the individual patient. First-line medications for HAE I/II include intravenous C1-INH, Haegarda<sup>®</sup> (C1-INH [human] subcutaneous injection), or Takhzyro. The guideline was written prior to approval of Orladeyo<sup>®</sup> (berotralstat capsules).

According to World Allergy Organization/European Academy of Allergy and Clinical Immunology guidelines (2021), it is recommended to evaluate for long-term prophylaxis at every visit, taking disease activity, burden, and control as well as patient preference into consideration.<sup>3</sup> The following therapies are supported as first-line options for long-term prophylaxis: plasma-derived C1-INH (87% agreement), Takhzyro (89% agreement), and Orladeyo (81% agreement). With regard to plasma-derived C1-INH, it is noted that Haegarda provided very good and dose-dependent preventative effects on the occurrence of HAE attacks; the subcutaneous route may provide more convenient administration and maintain improved steady-state plasma concentrations compared with the intravenous route. Of note, androgens are not recommended in the first-line setting for long-term prophylaxis. Recommendations are not made regarding long-term prophylaxis in HAE with normal C1-INH.

## References

1. Takhzyro<sup>®</sup> subcutaneous injection [prescribing information]. Lexington, MA: Takeda; February 2023.
2. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. *J Allergy Clin Immunol Pract.* 2021;9(1):132-150.e3.
3. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema: the 2021 revision and update. *Allergy.* 2022;77(7):1961-1990.

---

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. © 2023 Cigna.